文献速递银屑病与炎症性皮肤病

银屑病患者长期甲氨蝶呤治疗中无创检测非酒精性脂肪性肝炎与肝纤维化

Noninvasive Testing for Nonalcoholic Steatohepatitis and Hepatic Fibrosis in Patients With Psoriasis Receiving Long-term Methotrexate Sodium Therapy.
PubMed 文献 · JAMA Dermatol · 2017-01-01

本研究回顾性分析129例接受甲氨蝶呤治疗的银屑病患者,其中107例在治疗期间进行NASH FibroSure无创检测。结果显示患者肝脂肪变评分升高普遍,女性中累积甲氨蝶呤剂量与肝纤维化评分升高显著相关(Spearman ρ=0.21;除1例外所有患者未行肝活检。

要点

  • 银屑病患者肝脂肪变评分升高普遍,治疗前NSF检测中78.3%有脂肪变评分升高。
  • NASH FibroSure可用于监测银屑病患者甲氨蝶呤治疗期间纤维化评分变化。

核心结论

  • 银屑病患者肝脂肪变评分升高普遍,NASH FibroSure可用于监测甲氨蝶呤治疗期间纤维化评分变化,尤其在女性中可能有助于监测纤维化恶化风险。

研究设计与样本

  • 回顾性描述性分析,纳入2007年1月1日至2013年12月31日在单一机构皮肤科转诊中心接受甲氨蝶呤治疗并接受NASH FibroSure检测的银屑病患者队列。
  • 129例银屑病患者接受甲氨蝶呤治疗,其中107例(57女,50男;平均[SD]年龄83.3[13.5]岁)在治疗期间接受NASH FibroSure检测并纳入相关性分析。

主要发现

  • 129例接受甲氨蝶呤治疗的患者中,69例(53.5%)在开始治疗前接受NASH FibroSure检测,其中19例(27.5%)纤维化评分升高,54例(78.3%)脂肪变评分升高。
  • 队列中除1例外所有患者未行肝活检。

临床怎么用

  • NASH FibroSure可用于银屑病患者接受甲氨蝶呤治疗时监测肝纤维化评分变化,尤其女性患者可能有助于评估纤维化恶化风险。

局限性

  • 本研究为单中心回顾性描述性分析,样本量有限,结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The long-term implications of hepatotoxic effects in patients with psoriasis remains uncharacterized, and a method is needed for the noninvasive monitoring of the development and progression of hepatic fibrosis in patients with psoriasis receiving long-term methotrexate therapy. OBJECTIVE: To evaluate if NASH FibroSure, a noninvasive test for nonalcoholic steatohepatitis (NASH) and hepatic fibrosis, can be used for patients with psoriasis to aid in determining eligibility for methotrexate sodium (MTX) therapy, monitor for the development of MTX-induced hepatotoxic effects, and monitor for worsening of hepatic fibrosis scores during MTX therapy. DESIGN, SETTING, AND PARTICIPANTS: A retrospective descriptive analysis was conducted among a cohort of patients with psoriasis treated with MTX who underwent NASH FibroSure testing between January 1, 2007, and December 31, 2013, at a dermatology referral center at a single institution. Data analysis was performed from January 1 to December 31, 2014. MAIN OUTCOMES AND MEASURES: NASH FibroSure risk scores suggesting the development and progression of hepatic fibrosis in patients with psoriasis receiving long-term MTX therapy. RESULTS: Included in the institutional experience portion of the study were 129 patients with psoriasis undergoing treatment with MTX, while 107 patients (57 women and 50 men; mean [SD] age, 83.3 [13.5] years) underwent NASH FibroSure testing during MTX therapy and were eligible for correlation analysis. Of the 129 patients with psoriasis undergoing treatment with MTX, 69 (53.5%) underwent NASH FibroSure testing prior to starting MTX; 19 of those patients (27.5%) had elevated fibrosis scores, and 54 (78.3%) had elevated steatosis scores. Among the 107 patients who underwent NASH FibroSure testing during MTX therapy, the cumulative MTX dose corresponded to a statistically significant association of a higher NASH FibroSure hepatic fibrosis score in women (Spearman ρ = 0.21; P = .02) but not in men (Spearman ρ = 0.17; P = .11). All patients in the cohort except 1 were managed without a liver biopsy. CONCLUSIONS AND RELEVANCE: The patients with psoriasis in this study had a high prevalence of elevated hepatic steatosis scores. The NASH FibroSure test can be used to monitor changes in fibrosis score in patients with psoriasis receiving MTX. In a single-institution cohort, these results suggest that NASH FibroSure may be used, especially among female patients, to help monitor for risk of worsening fibrosis during MTX therapy.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Bauer B, Chyou PH, Stratman EJ, et al. Noninvasive Testing for Nonalcoholic Steatohepatitis and Hepatic Fibrosis in Patients With Psoriasis Receiving Long-term Methotrexate Sodium Therapy. JAMA Dermatol. 2017. PMID: 28832872. doi:10.1001/jamadermatol.2017.2083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。